QUOTE AND NEWS
DailyFinance  Apr 3  Comment 
PARSIPPANY, NJ -- (Marketwired) -- 04/03/14 -- The Medicines Company (NASDAQ: MDCO) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a biologic license application (BLA) for the investigational...
Benzinga  Apr 2  Comment 
Analysts at Credit Suisse downgraded ArcelorMittal (NYSE: MT) from “outperform” to neutral.” The target price for ArcelorMittal has been lowered from $20 to $17. ArcelorMittal's shares closed at $16.32 yesterday. Analysts at Piper Jaffray...
DailyFinance  Apr 2  Comment 
NEW ORLEANS, LA -- (Marketwired) -- 04/01/14 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 22, 2014 to file lead plaintiff...
TheStreet.com  Apr 1  Comment 
NEW YORK (TheStreet) -- The Medicines Co.  plunged more than 15% to a one-year low on Tuesday after the pharmaceutical company provided an update on its ongoing litigation after the close of trading on Monday. The company announced a judge in...
Benzinga  Apr 1  Comment 
The Medicines Company (NASDAQ: MDCO) shares touched a new 52-week low of $24.17 after the company provided an update on Angiomax patent litigation. NephroGenex (NASDAQ: NRX) shares reached a new 52-week low of $6.67. On Monday, NephroGenex...
Benzinga  Apr 1  Comment 
YOU On Demand Holdings (NASDAQ: YOD) slipped 18.13% to $4.02 after the company reported 2013 results. The Medicines Company (NASDAQ: MDCO) shares declined 15.82% to $23.92 after the company provided an update on Angiomax patent litigation....
StreetInsider.com  Apr 1  Comment 
YOU On Demand Holdings, Inc. (NASDAQ: YOD) 18% LOWER; reported 2013 pro-forrma revenue (exclusing Shandong Media) of $309,000 versus $5,000 reported last year. Net loss attributable to YOU on Demand common shareholders decreased to ($8.19 million)...
StreetInsider.com  Apr 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Medicines+Co.+%28MDCO%29+Slumps%3B+Issues+Update+on+Angiomax+Patent+Suit+%28HSP%29/9335906.html for the full story.
DailyFinance  Apr 1  Comment 
PARSIPPANY, NJ -- (Marketwired) -- 03/31/14 -- The Medicines Company (NASDAQ: MDCO) -- On March 31, 2014, Judge Andrews in the U.S. District Court of Delaware issued his Trial Opinion in The Medicines Company v. Hospira, Inc. The case involves...
DailyFinance  Mar 30  Comment 
WASHINGTON, DC -- (Marketwired) -- 03/30/14 -- The Medicines Company (NASDAQ: MDCO) today reported a presentation of a pooled analysis of 5,800 patients in the EUROMAX and HORIZONS-AMI trials, two international clinical trials comparing...




RELATED WIKI ARTICLES
 

Based in Parsippany, NJ, The Medicines Company (MDCO) is engaged in acquiring, developing, and marketing specialty pharmaceutical primarily for cardiovascular indications. Its leading product, Angiomax (bivalirudin), which was acquired from Biogen Idec, Inc. in 1996, is used as an anticoagulant in patients undergoing coronary angioplasty. The company's other late-stage products include Clevidipine and Cangrelor, both acquired from AstraZeneca several years ago. Clevidipine is an intravenous drug (calcium channel blocker) intended for the short-term control of blood pressure in patients undergoing cardiac surgery. Cangrelor is an intravenous anticoagulant, having potential uses in coronary angioplasty and cardiac surgery. The company sells its products through its own sales force and distributors. In 2006, sales of Angiomax helped generate $214.0 million revenue.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki